Evidence map›Paper›PMID 39741996›Full record

ArticleGlobal health & medicine2024

Higher FIB-4 index at baseline predicts development of liver cancer in a community-based cohort with viral hepatitis.

Makiko Kimura, Tomoki Nishikawa, Tetsuro Shimakami, Takeshi Terashima, Rika Horii, Masako Fukuda, Mika Yoshita, Noboru Takata, Tomoyuki Hayashi, Masaya Funaki and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Global health & medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Makiko KimuraDepartment of Gastroenterology, Kanazawa University Hospital, Ishikawa, Japan.
Tomoki NishikawaDepartment of Gastroenterology, Kanazawa University Hospital, Ishikawa, Japan.
Tetsuro ShimakamiDepartment of Gastroenterology, Kanazawa University Hospital, Ishikawa, Japan.
Takeshi TerashimaDepartment of Gastroenterology, Kanazawa University Hospital, Ishikawa, Japan.
Rika HoriiDepartment of Gastroenterology, Kanazawa University Hospital, Ishikawa, Japan.
Masako FukudaDepartment of Gastroenterology, Kanazawa University Hospital, Ishikawa, Japan.
Mika YoshitaDepartment of Gastroenterology, Kanazawa University Hospital, Ishikawa, Japan.
Noboru TakataDepartment of Gastroenterology, Kanazawa University Hospital, Ishikawa, Japan.
Tomoyuki HayashiDepartment of Gastroenterology, Kanazawa University Hospital, Ishikawa, Japan.
Masaya FunakiDepartment of Gastroenterology, Kanazawa University Hospital, Ishikawa, Japan.
Kouki NioDepartment of Gastroenterology, Kanazawa University Hospital, Ishikawa, Japan.
Hajime TakatoriDepartment of Gastroenterology, Kanazawa University Hospital, Ishikawa, Japan.
Kuniaki AraiDepartment of Gastroenterology, Kanazawa University Hospital, Ishikawa, Japan.
Tatsuya YamashitaDepartment of Gastroenterology, Kanazawa University Hospital, Ishikawa, Japan.
Masao HondaDepartment of Gastroenterology, Kanazawa University Hospital, Ishikawa, Japan.
Junko TanakaDepartment of Epidemiology, Infectious Disease Control and Prevention, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima City, Hiroshima, Japan.
Shuichi KanekoDepartment of Gastroenterology, Kanazawa University Hospital, Ishikawa, Japan.
Taro YamashitaDepartment of Gastroenterology, Kanazawa University Hospital, Ishikawa, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatitis B and C (HBV and HCV) testing has been performed in Japan since 2002 and is subsidized by central and prefectural governments. A follow-up program for HBV- or HCV-infected persons was started at that time in Ishikawa Prefecture. This study analyzed the long-term follow-up data from this program. In total, 1029 participants in the Ishikawa Hepatitis Follow-up Program (HBV-infected,

Indexed as

direct-acting antiviralshepatitis B virushepatitis C virusliver cancerliver cirrhosis

Identifiers

PMID39741996
PMCPMC11680450

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.